DeepMed Research

Topotecan

Generic Name: Topotecan

Brand Names: Hycamtin, Potactasol, Topotecan Hospira

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₃N_₃O_₅

CAS Number: 123948-87-8

Unique Ingredient Identifier: 7M7YKX2N15

Background: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.

Indication: 用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。

Associated Conditions: Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)

Clinical Trials

Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma

Phase 1

Completed

Conditions: Lymphoma
Small Intestine Cancer
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-05-03

Last Posted Date: 2013-07-11

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 17

Registration Number: NCT00005021

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.

Phase 2

Completed

Conditions: Carcinoma of Unknown Primary
Lung Cancer

First Posted Date: 2004-05-03

Last Posted Date: 2013-04-17

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 3

Registration Number: NCT00003943

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer

Phase 1

Terminated

Conditions: Ovarian Cancer

First Posted Date: 2004-05-03

Last Posted Date: 2012-09-26

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 3

Registration Number: NCT00005612

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia

Phase 1

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Myelodysplastic Syndromes
Thrombocytopenia

First Posted Date: 2004-04-27

Last Posted Date: 2013-06-26

Lead Sponsor: Drexel University College of Medicine

Registration Number: NCT00003619

Locations: 🇺🇸
Medical College of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Medical College of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States

Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: topotecan hydrochloride

First Posted Date: 2004-04-23

Last Posted Date: 2014-07-24

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 11

Registration Number: NCT00003735

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States

and more 35 locations

Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

First Posted Date: 2004-04-14

Last Posted Date: 2014-01-09

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 4

Registration Number: NCT00003917

Locations: 🇺🇸
Spartanburg Regional Healthcare System, Spartanburg, South Carolina, United States
🇺🇸
Veterans Affairs Medical Center - West Los Angeles, Los Angeles, California, United States
🇺🇸
Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital), Hines, Illinois, United States

and more 50 locations

S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2004-04-12

Last Posted Date: 2013-02-15

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 88

Registration Number: NCT00004137

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
CCOP - Central Illinois, Decatur, Illinois, United States
🇺🇸
Veterans Affairs Medical Center - Shreveport, Shreveport, Louisiana, United States

and more 82 locations

Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus

Phase 2

Terminated

Conditions: Sarcoma

First Posted Date: 2004-04-07

Last Posted Date: 2013-04-11

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00003156

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Tufts University School of Medicine, Boston, Massachusetts, United States

and more 43 locations

Combination Chemotherapy for Patients With Brain Cancer

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-04-06

Last Posted Date: 2011-10-27

Lead Sponsor: Dartmouth-Hitchcock Medical Center

Target Recruit Count: 20

Registration Number: NCT00002814

Locations: 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

First Posted Date: 2004-04-02

Last Posted Date: 2012-12-11

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Registration Number: NCT00006032

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy